A dvanced drug delivery systems (DDS) hold great promise for improving cancer therapy outcomes.
1
Anticancer DDS based on liposomes and/or polymers were approved recently for clinical use, already favorably impact cancer treatments, and cost about the same as free drugs. 2 Ligand-or antibody-directed delivery of drugs to tumors by binding to cancer cell surface receptors or antigens has found success in current DDS. 3 Nevertheless, future challenges remain, including improving specificity and stability, regulating bioavailability, and developing lower toxicity carriers. 3Ϫ5 Head and neck squamous cell carcinoma (HNSCC) is one of the most common types of cancer in oral oncology, representing ϳ6% of all cases and accounting for an estimated 650000 new cancers and ϳ350000 cancer deaths globally per year. 6, 7 Selectively targeting of squamous tumors is a long standing problem, since the drugs used lack specificity and cause severe side effects. 8, 9 Thus, developing new, effective tumor-targeted drug delivery systems is of high value.
Single-wall carbon nanotubes (SWNT) present remarkable opportunities to meet future DDS challenges. 10Ϫ12 Facile strategies are available to link biological molecules like proteins, DNA, and smaller molecules onto SWNTs. 13Ϫ15 The resulting solubilized nanotubes readily enter cells by endocytosis and by other mechanisms. 16, 17 Functionalized, solubilized SWNTs can transport peptides, proteins, genes, and DNA 18Ϫ22 across cell membranes with little cytotoxicity. 23, 24 SWNTs also provide very high surface area per unit weight for high drug loading. Carbon nanotubes and nanohorns have been tested in vitro for delivery of drugs.
25Ϫ28
However, assessing the in vivo efficacy of nanotubes loaded with anticancer drugs is critical. Several previous reports have demonstrated in vivo targeting of tumors with carbon nanotubes in animal models, but with no drug cargo delivered. 29, 30 While the present paper was in preparation, a report appeared describing nontargeted delivery of paclitaxel on SWNTs in mice. 31 Herein, we provide the first demonstration that targeted SWNT drug delivery results in rapid decrease of tumor size in mice compared to a nontargeted SWNT control. SWNTs were functionalized with first-line anticancer drug cisplatin 32, 33 and epidermal growth factor (EGF) to make a DDS that selectively targets squamous cancer cells (Figure 1a ,b). This new DDS capitalizes on the specific affinity of EGF for its cognate cell-surface receptor (EGFR), overexpressed in most squamous cancer cells, 34Ϫ36 as a guidance mechanisms to deliver therapeutic drug to the tumor. The present study demonstrates first that drug-laden SWNTs can selectively enter and kill cancer cells in vitro by utilizing EGF-EGFR interactions, and then demonstrates efficacy in an animal model.
RESULTS
Preparation and Characterization of SWNT Bioconjugates. SWNTs were oxidized in acid to provide carboxylate groups on ends and sidewalls. 10, 12 These shortened nanotubes were used to prepare SWNTϪcisplatinϪEGF bioconjugates for cell killing, and SWNT-Qdot-EGF (Figure 1a) to visualize 37 the bioconjugates in cell cultures and mice. Uptake of the bioconjugates into target cells was visualized by luminescence of green emitting Qdot525 and red emitting Qdot605, Qdots and EGF were attached by amidization to the carboxylated SWNTs using aqueous 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (EDC) as promoter.
The resulting bioconjugates were characterized by transmission electron microscopy (TEM). When coupling agent EDC was omitted from bioconjugation reactions, nanotube-like images appeared striated, with widths suggesting small bundles of 5 to 8 of individual 1.0 to 1.4 nm diameter SWNTs, but with no particles attached (Figure 1c) . In contrast, with EDC in the bioconjugation mixture, decoration of nanotubes with visible small particles attached was observed ( Figure 1d ). The QDots are ϳ4 nm in average diameter, roughly corresponding to the diameters of spherical features attached to the nanotube bundles in Figure 1d . Average nanotube dimensions with dispersions were estimated from TEM as 110 Ϯ 50 nm length and 10 Ϯ 3 nm width.
EGF attachment was confirmed by using fluorescein-labeled EGF to make EGFϪSWNT bioconjugates with increased luminescence compared to controls with no label. Luminescence was also observed from fluoresceinlabeled antibodies to EGF when bound to EGFϪSWNT further confirming EGF attachment (Supporting Information, Figure S1 ). Difference absorption spectroscopy was used to measure 3 mg mL Ϫ1 EGF per 1 mg mL
Ϫ1
SWNT in dispersions, which translates to an average of 36 Ϯ 10 EGF molecules per 100 nm length of SWNT. Cisplatin [Cl 2 Pt(NH 2 ) 2 ] was attached via complexation with the nanotube carboxylate group, a ligand exchange reaction reported previously for carboxylic acids (RCOOH) attached to peptides that gave R-COO-PtCl(NH 2 ) 2 and (R-COO-) 2 PtCl(NH 2 ) 2 complexes active against cancer. 38 The amount of cisplatin measured by difference UV absorbance of adsorbate solutions before and after attachment to SWNTs. Cisplatin was also detected by scanning transmission electron microscopy and energydispersive X-ray analysis (EDAX) 39 ( Figure 1e ) (Supporting Information, Figure S2 ). The final SWNTϪ cisplatinϪEGF dispersions used below contained 1.3 M cisplatin and 0.25 mg mL Ϫ1 SWNTs. All bioconjugates were used within several days of preparation. Selective Targeting of HNSCC Cells with SWNT Bioconjugates in Vitro. We next explored whether SWNT functionalized with EGF targets EGFR on HNSCC cultures in vitro (Figure 1b) . Representative HNSCC cell lines (HN12, HN13; see Supporting Information for cell culture conditions) previously shown to overexpress EGFR 40 were incubated for 10 min with freshly prepared SWNTϪQdot525ϪEGF (SQE) bioconjugates. The Figure S3 ). Cells with diminished levels of EGFR showed low, basal uptake of nanotubes regardless of EGF presence, but did not specifically internalize SWNTϪQdot525ϪEGF (Supporting Information, Figure S4 ,aϪd). This finding is reflected by quantitative analysis of the confocal micrographs (Figure 2g) , in which the percentage of cells with internalized SWNTϪQdot525ϪEGF was Ͼ75% for nontransfected HN13 cells with EGFR compared to Ͻ20% for controls lacking or expressing low levels of EGFR. Analysis of pixel intensities in the micrographs also indicated a similar profile for the internalization (Supporting Information, Figure S5 ).
Collectively, these results suggest that EGFϪEGFR ligandϪreceptor interactions mediate efficient internalization of SWNTϪQdotϪEGF, most likely by receptormediated endocytosis. 16, 43 A fraction of cells lacking EGFR internalized some SWNTϪQdotϪEGF, suggesting a secondary mechanism possibly related to that in systems where endocytosis is not possible. 17 Internalized SWNTϪQdot525ϪEGF bioconjugates were also observed by TEM 44 in HN13 cells. In cells exposed to SWNTϪQdot only, SEM features resembling nanotubes were not detected ( Figure 2h ). In contrast, SQE-treated cells clearly showed tubular structures indicating the presence of the nanotube bioconjugates in close proximity to the perinuclear region ( Figure 2i ). Nanotube bioconjugates were also found distributed around lysosomes and within the cytoplasm. The nanotubes ob- served in TEM are most likely aggregates, since they have diameters of ϳ10 nm, much larger than the ϳ1.4 nm average diameter of single nanotubes. Lengths of tubular TEM features of 50Ϫ300 nm were similar to the 40Ϫ400 nm lengths of the oxidized nanotube starting material. Few, if any, SQ bioconjugates (without EGF) were found within the plasma membrane, implying that they were unable to reach the cell nuclei, whereas SQE bioconjugates clearly were rapidly taken up, as evidenced by their accumulation in the perinuclear region ( Figure 2i , and Supporting Information, Figure  S6a ,b). Two-Photon Video Imaging of Mice Bearing HNSCC Tumor Treated with SWNT Bioconjugates. We next focused on determining if the EGF-EGFR interaction would direct nanotube bioconjugates to tumors in vivo using the HNSCC xenograft model. HN12 cells that also express EGFR 45 were used to induce tumors in athymic mice. Once tumors had grown to approximately 7Ϫ10 mm, nuclei and vasculature were visualized by intravital 3-color imaging through systemic injection of Hö echst and 500 KDa FITC-labeled dextran, respectively. SWNTϪ Qdot605ϪEGF and control SWNTϪQdot605 (no EGF) were delivered systemically (Supporting Information Figure S7 and video S8) and monitored for their relative distribution. The videos are the primary data in these studies, although in the main paper we can only display individual still frames indicating a result at one instant in time. In the videos, SWNTϪ Qdot605ϪEGF could be readily observed moving with the blood flow, diffusing out from the vasculature within ϳ20 min postinjection and rapidly accumulating within the tumor mass (Supporting Information videos S9 and S10, and Figure 3b,c) . Control bioconjugates without the targeting ligand were also detected within the blood vessels immediately after injection. These controls were rapidly cleared and never found accumulated in the tumor cells (Supporting Information video S11, and Figure 3a) .
Lesions from similarly treated mice were also analyzed by confocal microscopy. Data show that only SWNTϪQdot605ϪEGF bioconjugates accumulated within the tumor mass (Figure 3e,f) . Control experiments in which ligandϪ receptor interactions were absent showed little or no uptake by the tumor cells (Figure 3d ). The intravital twophoton and confocal analysis also suggest that the Qdots remained attached to the nanotube bioconjugate, as the SWNTϪQdot605 bioconjugate was internalized by the tumor cells only when the EGF was included on the SWNTϪQdot bioconjugate. This can be verified by comparing EGF-free controls (Figures 3a and  d) with the full bioconjugate (Figures 3b,c,e,f) . The red Qdot-nanotube control conjugate does not give a color in the tumor tissue, only the full bioconjugate in which both Qdots and EGF are attached to the nanotubes, suggesting that it arrives in the tumor region intact.
In Vitro Killing of HNSCC Cells Using SWNT؊Cisplatin؊EGF. Figure 4a shows optical micrographs of exponentially grown HN13 cells adhered to an underlying plate. After addition of SWNTϪcisplatinϪEGF (SCE) to the cells and incubating for 10 min, the cells showed minor morphological changes and dark nanotube bioconjugates on their surfaces (Figure 4b ). After being washed in PBS and placed in fresh media, most of the nanotubes were removed, leaving only those bound to EGFR on the www.acsnano.org cell surfaces (Figure 4c) . After an additional 7Ϫ12 h incubation, a profound change in cell morphology was observed (Figure 4d ). The majority of the cells were detached and floating, indicative of cell death. Apoptosis of HN13 cells treated with SWNTϪ cisplatinϪEGF was confirmed by the TUNEL assay (supporting Figure S12) . Figure S3) . Cell proliferation was estimated through mitochondrial activity (MTT assay). 46, 47 Assays were done using SWNTϪcisplatinϪEGF and controls (cells only, cisplatin alone, and cisplatin-SWNT) using HN13 cells and those with EGFR knockdown siRNA or control siRNA without knockdown (Figure 4e) . The cisplatin concentration used was within levels detected in serum of cancer patients receiving this drug (1Ϫ10 M). Cells treated with SWNT, cisplatin (10 M, clinically relevant), and cisplatinϪSWNT without EGF showed only very small differences in growth. However, for HN13 cells and cells pretreated with control siRNA, cell growth was hindered (ϳ25Ϫ50%) when treated with SWNTϪ cisplatinϪEGF (1.3 M, SCE in Figure 4e ), while cells lacking EGFR were minimally affected. All cells treated with high doses of free cisplatin (300 M, clinically irrelevant) had greatly decreased cell growth showing the efficacy of the drug under these conditions and serving as a positive control. Cell proliferation results with SWNTϪtransplatinϪEGF, an isomer of cisplatin (supporting Figure S13 ), were consistent with Figure 4B and with the lower anticancer activity of this drug. Together, these results supported the high specificity of SWNTϪcisplatinϪEGF bioconjugates as a receptorguided anticancer drug delivery system.
Further studies were done with SAA cells, that is, NIH3T3 cells that overexpress EGFR, and NIH3T3 cells which express much less EGFR than HN13 cells. Western blot assays for EGFR confirmed the expected high or low levels of EGFR (supporting Figure S14) . Cell proliferation data (Figure 4f) show that after incubation with SWNTϪcisplatinϪEGF, growth was hindered in HN13 and SAA cells which overexpress EGFR, but growth of NIH3T3 cells was largely unaffected. Nanotubes alone, 10 M free cisplatin, SWNTϪEGF and SWNTϪcisplatin demonstrated negligible effects on growth in any cell lines. Cells treated with a large dose of cisplatin (300 M) again resulted in low cell proliferation indicative of severe cytotoxicity. A key result is that SWNTϪcisplatinϪEGF dispersions with 1.3 M cisplatin were more effective at cell killing than 10 M free cisplatin.
In Vivo Tumor Targeting of SWNT Bioconjugates with Cisplatin. HN12 cells that also overexpress EGFR were treated with SCE in a similar way as HN13 cells and the cell proliferation was tested using MTT assay (supporting Figure S15) . These cells were then used to induce tumors in nude athymic mice. Once these tumors had grown to approximately 7Ϫ10 mm, the mice were given iv injections of the nanotube bioconjugates along with the controls through the tail vein. The mice were monitored for ϳ2 weeks for their tumor growth pattern. Figure  5a shows tumor growth in the mice for both control (SWNTϪcisplatin) and the positive bioconjugates (SWNTϪcisplatinϪEGF) for 10 days. The mice treated with an unguided nanotube bioconjugate (control) did not show tumor regression and the tumor kept on growing. Mice treated with targeted nanotube bioconjugate (positive) showed considerable slowdown in the tumor growth indicating a selective targeting of SWNTϪcisplatinϪEGF into the HNSCC cancer microenvironment. Raman characterization was done on tumor cryosections to detect the SWNTs. Figure 5b shows the signature G-band of SWNT obtained from a positive mouse, 48 while the Raman peaks were not detected in the control mice (supporting Figure S16) . Figure 5c 
Biodistribution in Mice.
We analyzed vital organs and tumors from mice injected with the nanotube bioconjugates to monitor the short-term biodistribution of SWNT bioconjugates. Analysis of these images suggested that the SWNT-Qdot605-EGF bioconjugates are much more abundant within the microenvironment of the tumor in comparison to controls at 45 min postinjection ( Figure 6 ). Quantitative analysis of image intensities indicated a significantly larger uptake of nanotube bioconjugates within the tumor section when the targeting ligand EGF was incorporated into the bioconjugates (supporting Figure S17) . Smaller amounts of nanotube bioconjugates were found within the spleen, lung, liver, kidney and heart, as shown by the red Qdot color, and this occurred regardless of the presence of EGF. The biodistribution profile of our nanotube bioconjugates showed accumulation in different vital organs as also reported for nanotubes solubilized with PEG.
23,29

DISCUSSION
Results above clearly demonstrate for the first time that SWNTs bioconjugated with a targeting ligand and cisplatin is superior to untargeted drug-SWNT bioconjugates for selective cancer chemotherapy in living animals (Figures 3 and 5a) . Administration of the SWNTϪ cisplatinϪEGF bioconjugate caused a very significant tumor volume decrease compared to SWNT-cisplatin control, albeit with limited numbers of mice ( Figure 5 ). Furthermore, in vitro imaging (Figure 2 www.acsnano.org evidence for nontargeted nanotubes in the cells in control experiments. In the mouse tissue sections, the identity of the dark cylindrical images as nanotubes was confirmed with Raman spectroscopy ( Figure  5b ). Short-term biodistribution studies of these SWNT bioconjugates showed the presence of nanotube bioconjugates in various vital organs of the mice, but in much smaller amounts than in the tumors ( Figure  6 ). Clearly, long and shortterm toxicity of these and other nanotube-drug bioconjugates must be fully characterized prior to successful translation to the clinic. While needle-like multiwall CNTs Ͼ 20 m show serious toxic effects in animals, 50 shortened nanotubes (e.g., Ͻ1 mm) functionalized with biomolecules or chemical groups to provide good aqueous solubility or dispersability show negligible cytotoxicity even at high concentrations. 51Ϫ54 On the basis of these and related studies, more efficient solubilization of nanotube bioconjugates may aid their rapid clearance and minimize toxic effects. The precise assessment of biodistribution of nanotube bioconjugates as well as their long-term cytotoxicity 55 in vivo is currently under further evaluation in our laboratories.
In vitro and in vivo studies herein provide clues to the mechanism of targeting and internalization of the targeted nanotube DDS into cancer cells. Internalization of the EGFR targeted SWNT-EGF bioconjugates by HNSCC cells was very fast and selective (Figure 2 ). Twophoton intravital videos, the primary data for the in vivo imaging, played a key role in tracking the fate of nanotube bioconjugates in living species, and provided direct in vivo evidence of targeted SWNTϪQdotϪEGF bioconjugates being rapidly internalized into cancer tumors. The videos clearly show that within 20 min of administration the SWNTϪQdotϪEGF bioconjugates accumulated within the periphery of the cell nuclei (Figure 3) . On the contrary, the nontargeted SWNTϪ QdotϪEGF bioconjugates were visualized entering the vasculature but being rapidly cleared from the tumor region during a similar 20 min period. This is best visualized by viewing the time lapse videos themselves (Supporting Information videos, S8ϪS11), as Figure 3 shows only the images at specific points in time.
Complementing these in vivo studies suggesting the effectiveness of targeting with EGF, in vitro cell proliferation assays showed definitively that ligandϪreceptor (EGF-EGFR) interactions are key to the targeting and killing of the cancer cells (Figure 4) .
CONCLUSION
This paper presents direct evidence that oxidized SWNTs bioconjugated with cisplatin and specific receptor ligand EGF can selectively and efficiently target squamous cancer cells that overexpress EGFR as demonstrated by in vivo and in vitro imaging and cancer cell viability. EGFR-targeted bioconjugates were much more efficient at killing cancer cells than untargeted controls containing the same drug. Moreover, results suggest a major ligand receptor-mediated endocytosis pathway for cellular uptake both in vitro and in vivo, as suggested previously from in vitro studies, 16, 18 accompanied by a less specific, less efficient secondary cell-internalization mechanism. While short-term biodistribution results of the tumor targeting SWNT DDS are promising ( Figure  6 ), forward translation of targeted nanotube DDS will require long-term toxicity, distribution, and clearance studies in animal models. Nevertheless, findings herein strongly suggest the feasibility of future applications of SWNT bioconjugates in cancer-targeted drug delivery.
METHODS
Bioconjugation of Cisplatin, EGF, and Qdots to SWNTs. SWNTs were HiPco nanotubes from Carbon Nanotechnologies, Inc. Human epidermal growth factor (EGF), fluorescein and 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (EDC) from Sigma-Aldrich was dissolved in PBS immediately before use. Amino (PEG) quantum dot nanocrystals (Qdot; 525 nM)
were from Invitrogen. Cisplatin [cis-diammineplatinum(II) dichloride] was from the Development Therapeutics Program (National Cancer Institute), and trans-platinum(II)diammine dichloride was purchased from Sigma-Aldrich.
Shortened, oxidized SWNTs (0.5 mg/ml) were dispersed in PBS by sonication for 5 min followed by incubation with 2 mg/mL EDC for 1 min at room temperature (RT), after which samples were immediately vortexed. Next EGF was added to- gether with either cisplatin (10 M in DMSO) or Qdots (8 M solution), and the resulting mixture reacted for an additional 1 h at 37°C in a thermomixer. These samples were then centrifuged at 1300 rpm for 20 min and the resulting SWNTϪcisplatinϪEGF (SCE) or SWNTϪQdotϪEGF (SQE) were resuspended in 100 L DMEM and used immediately. Control SCE and SQE (minus EGF or cisplatin or Qdot), and bioconjugates where cisplatin was replaced with trans-platinum(II)diammine dichloride were prepared similarly. Cell Proliferation (MTT) Assay. Cells were grown to 50Ϫ60% confluency overnight in 96 well plates. Next, the media was aspirated and the cells incubated with fresh media containing SCE and control complexes for 10 min. After 3 washes in PBS, cells were incubated for an additional 24 h in fresh media. MTT was assessed using the CellTiter 96 AQ One Solution Cell Proliferation Assay kit (Promega, MI), and measured optically at 570 nm.
Animal Studies. All animal studies were carried out according to NIH-approved protocols, in compliance with the Guide for the Care and Use of Laboratory Animals. Female athymic (nu/nu) nude mice (Harlan SpragueϪDawley, Indianapolis, IN), 4Ϫ6 weeks old and weighing 18 to 20 g were used in the study, housed in appropriate sterile filter-capped cages, and fed and given water ad libitum. HN12 cells maintained as described (see above) were transplanted subcutaneously into the flanks of mice to induce HNSCC tumor xenografts as previously described.
46
Biodistribution Studies. Animals with xenografts of approximately 7Ϫ10 mm in length were injected intravenously (iv) with Hö echst (3342) and FITC (fluorescein isothiocyanate)-dextran (500 kDa) stains (Invitrogen) followed by SWNTϪQdot605ϪEGF or SWNTϪQdot605 (0.6 mg in 200 L PBS) bioconjugates. After euthanasia (ϳ1 h post injection), vital organs (heart, kidney, liver, lung, spleen) and tumors were removed from the animals, and part fixed and paraffin embedded, or frozen and embedded in optimal cutting temperature compound Tissue-Tek OCT (Sakura Finetek USA, Inc., Torrance, CA). For in vivo biodistribution studies, color channel from each of the confocal images (see above) was acquired using a triple filter set as high-resolution TIFF images ( Figure 5) .
Confocal Microscopy. HN13 and corresponding siRNA transfected cells were grown 50Ϫ60% confluent on glass coverslips, treated with SWNTϪQdotϪEGF and SWNTϪQdot bioconjugates as described above and, incubated for an additional 1 h posttreatment. Cells were next fixed in 3.5% PBS-formaldehyde solution for 15 min at RT, followed by rinses in PBS (3 ϫ for 2 min each), permeabilization in 0.5% PBS-Triton X100 solution for 5 min at RT, after which the cells were blocked with 3% PBSϪBSA solution for 30 min at RT. Cells were next incubated with AlexaFluor 647-conjugated phalloidin (1/500 dilution in PBS for 45 min at RT; Invitrogen). Nuclei were revealed using propidium iodide (1/10000 dilution in H 2 O for 5 min at RT; Invitrogen). After 5ϫ washing, samples were mounted onto SuperFrost microslides with Vectashield mounting medium (Vector Laboratories, Inc., Burlingame, CA). Eight micrometer cryosections of xenografts retrieved from mice that had been injected intravenously with SWNTϪQdotϪEGF and SWNTϪQdot bioconjugates were prepared, fixed (in 90% ethanol for ϳ30 s) mounted and analyzed directly under confocal microscope without any additional staining. In all cases, confocal acquisitions were performed with a TCS/SP2 Leica microscope and pictures are representative of at least three independent experiments. Images were processed and analyzed using Metamorph Premier 7.1 software (Molecular Devices, Sunnyvale, CA). Statistical analyses were conducted with Prism 4.0 software (GraphPad Inc. San Diego, CA).
Transmission Electron Microscope Imaging. Electron microscope imaging was done using FEI CM120 transmission electron microscope (TEM; equipped with a Gatan GIF100 image filter) operating at a beam energy of 120 keV for in vitro and in vivo studies of SWNT bioconjugates and Tecnai TF30 TEM (FEI, Hillsboro, OR) equipped with a Gatan Ultrascan 1000 CCD camera (Gatan, Pleasaton, CA) for characterization of SWNT bioconjugates. EDX analysis for Pt was done using a VG HB501 dedicated scanning transmission electron microscope operating at 100 kV and equipped with an Oxford energy-dispersive X-ray microanalysis system. 56 (Full details in Supporting Information file.) Two-Photon Intravital Video Microscopy. Time-lapse acquisitions were performed using an Olympus IX81 microscope (Olympus, Melville, NY) customized for two-photon microscopy. Fluorescent probes were excited with an infrared beam (800 nm) generated by a tunable Ti:Sapphire femtosecond laser, Chameleon Ultra II (Coherent, Santa Clara, CA). The power was modulated using a combination of neutral density filters (Chroma Technologies, Rockingham, VT) and maintained at the specimen between 10Ϫ30 mW. The diameter of the beam was modulated using a beam expander (LSM Technology Inc., Shrewsbury, PA) and directed into a Fluoview 1000 scanning head (Olympus, Melville, NY). The beam was focused on the specimen via a water immersion objective (UPLSAPO 60X NA 1.2; Olympus America Inc.) mounted on an objective inverter (LSM technologies, Stewartstown PA). A carbomer 940-based gel (Snowdrift farm, Tucson, AZ) was used as optical coupling media. The emitted light was gathered through the same objective and directed into a custom-made array of three nondescanned detectors that were installed on the right port of the microscope (LSM Technology Inc., Shrewsbury, PA). Three cooled PMTs (R6060Ϫ12, Hamamatsu Photonics K.K, Hamamatsu, Shizuoka Prefecture, Japan) were used to detect the spectrally separated emitted light. Hö echst fluorescent signal was detected on the first PMT (dichroic mirror, 510 nm; barrier filter, 400Ϫ480 nm). FITC was detected on the second PMT (dichroic mirror, 570 nm; barrier filter, 505Ϫ560 nm) and Qdot605 on the third PMT (barrier filter, 590Ϫ650 nm). The animals were anesthetized by an intraperitoneal injection of a mixture of ketamine and xylazine 125 and 25 mg/kg body weight, respectively. The anesthetized animals were placed on an adjustable stage on the side of the microscope. The stage was preheated to protect animals from hypothermia. For the systemic injections, the tail artery was surgically exposed, and a small incision was performed to insert a fine catheter connected to a 1 mL syringe filled with saline (supporting Figure  S7) . The nuclei were stained by systemic injection of 2.5 g of Hö echst (3342) and the blood volume was labeled by injection of 20 g of FITC-Dextran (500 kDa). Both probes were purchased from Invitrogen and dissolved in saline. Approximately 0.06 mg of SWNTϪQdot605-EGF and SWNTϪQdot605 (control) bioconjugate suspended in 200 L PBS was injected systemically. Timelapse acquisition was started just prior to injecting the bioconjugates and continued for up to 1 h. Acquisitions speed was set 0.3 frames per second. Videos were assembled with Metamorph (Molecular Devices, Sunnyvale, CA) and compressed with QuickTime Pro.
